Samrat Pharmachem Limited , a pharmaceutical chemicals manufacturer, has released its financial results for the second quarter of fiscal year 2026, ending September 30, 2025. The company reported a mixed performance, with revenue growth accompanied by a net loss.

Financial Highlights

Note: All financial figures are in Rs. lakhs, except for EPS

Revenue Growth Amidst Challenges

Samrat Pharmachem demonstrated resilience in its top-line performance, with revenue increasing to Rs. 7,887.03 lakhs in Q2 FY26, up from Rs. 7,172.22 lakhs in the same quarter of the previous year. This represents a year-on-year growth of approximately 10.0%, indicating the company's ability to expand its sales despite challenging market conditions.

Profitability Concerns

Despite the revenue growth, the company reported a net loss of Rs. 58.73 lakhs for the quarter. This marks a shift from the previous year, although the comparative profit figure for Q2 FY25 was not provided in the available data.

Half-Year Performance

The company's financial struggles appear to have extended throughout the first half of FY26. For the six-month period ended September 30, 2025, Samrat Pharmachem reported a widened loss of Rs. 81.62 lakhs, compared to a profit of Rs. 472.66 lakhs in the corresponding period of the previous year. This represents a substantial decline in profitability.

Earnings Per Share

The earnings per share (EPS) for the half-year stood at negative Rs. 2.64, reflecting the impact of the losses on shareholder value. The company did not provide a comparative EPS figure for the previous year in the released data.

Management Commentary

The Board of Directors approved these unaudited standalone financial results at a meeting held on November 14, 2025. The meeting, which commenced at 14:00 hours and concluded at 20:30 hours, also involved a review by the Audit Committee.

Business Segment

Samrat Pharmachem continues to operate in a single business segment, focusing on the manufacture of pharmaceutical chemicals. This specialization may provide the company with a focused approach to its operations, but it also exposes it to sector-specific risks and market fluctuations.

Looking Ahead

As Samrat Pharmachem navigates through these challenging times, investors and stakeholders will be keenly watching for signs of a turnaround in profitability. The company's ability to sustain and capitalize on its revenue growth while addressing the factors contributing to its current losses will be crucial for its future performance.

The pharmaceutical chemicals sector remains dynamic, influenced by various factors including regulatory changes, raw material costs, and global demand for pharmaceutical products. Samrat Pharmachem's performance in the coming quarters will be instrumental in determining its trajectory in this competitive landscape.

Samrat Pharmachem Limited , a prominent player in the pharmaceutical industry, has announced the reappointment of three key executives for extended five-year terms, effective April 1, 2026. This strategic move, subject to shareholder approval at the upcoming 33rd Annual General Meeting, aims to ensure continuity in the company's leadership and leverage the extensive experience of its long-standing directors.

Leadership Continuity

The Board of Directors has reappointed the following executives:

1. Lalit Mehta (88) - Reappointed as Chairman & Managing Director

   • Over 58 years of pharmaceutical industry experience
   • First-generation entrepreneur and company promoter
   • Science and Law graduate

2. Rajesh Mehta (61) - Reappointed as Executive Director

   • Chartered Accountant with 33 years of experience in Finance and Corporate Affairs
   • Commerce graduate

3. Megh Mehta (32) - Reappointed as Executive Director

   • Over 10 years of experience in Marketing and Administration
   • Holds degrees in Management Studies, Commerce, and Professional Management

Family Ties and Expertise

The reappointments highlight the strong family ties within Samrat Pharmachem's leadership:

• Lalit Mehta is the father of Rajesh Mehta and grandfather of Megh Mehta
• This family dynamic brings a unique blend of experience and fresh perspectives to the company's management

Board Composition

Following these reappointments, Samrat Pharmachem's board will consist of seven directors:

• Three executive directors (the reappointed family members)
• Four independent non-executive directors

This structure aims to balance family leadership with independent oversight, promoting good corporate governance practices.

Terms of Appointment

The reappointments are for a five-year term, from April 1, 2026, to March 31, 2031, demonstrating the company's commitment to long-term stability and growth. The decision was made by the Board of Directors on July 16, 2025, based on recommendations from the Nomination and Remuneration Committee.

Shareholder Approval and Regulatory Compliance

These reappointments are subject to shareholder approval at the forthcoming 33rd Annual General Meeting. The company has duly informed the BSE Limited of these changes, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Samrat Pharmachem's decision to retain its experienced leadership team signals confidence in its current management strategy and sets the stage for continued growth and innovation in the pharmaceutical sector.